Podcast

BioSpace

Author
BioSpace
Feed episode count
247
Official site
https://www.biospace.com/
RSS
https://api.riverside.fm/hosting/3SxyDAXU.rss
JSON
/v1/public/podcasts/biospace-6696251
Markdown
/podcast/biospace-6696251.md

Summary

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Episodes

Jul 15, 2026 · not_requested

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

Duration seconds
1282

Jul 14, 2026 · not_requested

Bonus: Q2 2026 Job Market Update

Duration seconds
541

Jul 10, 2026 · not_requested

From sequence to scale: Gene editing’s new era in biologics manufacturing

Duration seconds
1241

Jul 8, 2026 · not_requested

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Duration seconds
1024

Jul 1, 2026 · not_requested

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

Duration seconds
1374

Jun 25, 2026 · not_requested

The Golden Triangle and the gaps: Rethinking UK biotech

Duration seconds
1177

Jun 24, 2026 · not_requested

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

Duration seconds
1296

Jun 18, 2026 · not_requested

From fragile skin to living medicine: Lessons from RDEB

Duration seconds
1303

Jun 17, 2026 · not_requested

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Duration seconds
1533

Jun 10, 2026 · not_requested

Portugal, Spain and the new biotech frontier

Duration seconds
1233

Jun 10, 2026 · not_requested

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Duration seconds
1502

Jun 3, 2026 · not_requested

Rethinking hair loss treatment

Duration seconds
1305

Jun 3, 2026 · not_requested

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

Duration seconds
1624

May 28, 2026 · not_requested

France’s biotech ecosystem: science, capital and scale

Duration seconds
1260

May 27, 2026 · not_requested

Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

Duration seconds
1472

May 21, 2026 · not_requested

Inside Germany’s biotech capital infrastructure and innovation engine

Duration seconds
1397

May 20, 2026 · not_requested

FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum

Duration seconds
1608

May 14, 2026 · not_requested

From MSCs to iPSCs: building the cell therapy future

Duration seconds
1225

May 13, 2026 · not_requested

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

Duration seconds
942

May 7, 2026 · not_requested

Fibrosis, IPF and the search for better therapies

Duration seconds
1080

May 6, 2026 · not_requested

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

Duration seconds
1350

Apr 30, 2026 · not_requested

What makes life science angel investment work?

Duration seconds
1300

Apr 29, 2026 · not_requested

Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions

Duration seconds
1334

Apr 23, 2026 · not_requested

The next era of diabetes management

Duration seconds
1302

Apr 22, 2026 · not_requested

Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win

Duration seconds
1568

Apr 16, 2026 · not_requested

Funding the Future of European Biotech

Duration seconds
1210

Apr 15, 2026 · not_requested

J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer

Duration seconds
1073

Apr 14, 2026 · not_requested

Bonus: Q1 2026 Job Market Update

Duration seconds
513